Group 1 - The company held its second extraordinary general meeting of shareholders on November 24, 2025, with both on-site and online voting options available [3][4][5] - A total of 294 shareholders and representatives attended the meeting, representing 93,527,063 shares, which is 47.6915% of the total voting shares [5][6] - The meeting approved several proposals, including amendments to the company's articles of association and various management rules, with overwhelming support from shareholders [7][8][9] Group 2 - The company ensured that small and medium-sized investors had a separate voting count for certain proposals to enhance their participation [2] - The legal opinions provided by Zhejiang Tian Ce Law Firm confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations [18] - The company disclosed that the resolutions from the meeting would be available for review, including the legal opinions and meeting resolutions [19]
浙江昂利康制药股份有限公司2025年第二次临时股东大会决议公告